Paliperidone Palmitate for Schizophrenia: Research on New Innovative Treatment for Unmet Needs

CONFERENCE REPORTER

Christoph Correll, MD, shares more on his research on paliperidone palmitate 6-month, which kept a significant number of patients with schizophrenia relapse free for up to 3 years following treatment according to data presented at 2023 Psych Congress®.

Dr Correll is professor of psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and a medical director of the Recognition and Prevention (RAP) program at Zucker Hillside Hospital. He also currently serves as professor and chair of the Department of Child and Adolescent Psychiatry at Charité University Medicine in Berlin, Germany.

The articles and interviews featured on this page were developed by Psychiatric Times editorial staff and contributors based on presentations delivered at Psych Congress®, an annual conference produced by HMP Global, LLC. Psychiatric Times is an independent publication and is not affiliated with, endorsed by, or sponsored by HMP Global, LLC. All content on this page reflects the independent editorial judgment of Psychiatric Times and does not represent the views, positions, or communications of HMP Global, LLC.